Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 ...
() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in ...
Researchers at Karolinska Institutet in Sweden have discovered that some natural killer cells, NK cells, temporarily reside ...
In today’s fast-paced world, maintaining a strong immune system is more important than ever. Many families are turning to natural approaches to support overall health and wellness, and family ...
Dr. Erin Theisen, who co-led the study, said this discovery could help treat many diseases where inflammation is a problem.
Your immune system is a network of cells, tissues, and organs that fight off infection. Your immune system can be affected by ...